COLLIDION, INC.

Spectrum Antimicrobials, Inc. Announces the Launch of its Animal Health Division

Retrieved on: 
Tuesday, December 22, 2020
Chemical substances, Chemistry, Physical sciences, Disinfectants, Hypochlorous acid, Cleanser, Animal shelter, Veterinarian

PETALUMA, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Spectrum Antimicrobials, Inc., announces the launch of Vetricept Skin and Wound Care Cleanser, the first product launch in the Companys new Animal Health Division.

Key Points: 
  • PETALUMA, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Spectrum Antimicrobials, Inc., announces the launch of Vetricept Skin and Wound Care Cleanser, the first product launch in the Companys new Animal Health Division.
  • The new technology stays active in the presence of blood serum and other organic loads, unlike all other versions of HOCl.
  • In addition, they had teams providing veterinary medical care at emergency animal shelters, caring for their wounds daily.
  • Spectrum is anticipating the launch of other Animal Health products in the U.S. and internationally in 2021.

Spectrum Antimicrobials, Inc. Announces Breakthrough Drug Candidate for Prevention and Treatment of Pulmonary Infections

Retrieved on: 
Monday, November 16, 2020
Biocides, Health sciences, Branches of biology, Infectious diseases, Health, Antimicrobial, Antiviral drug, Infection, Lower respiratory tract infection, Respiratory tract

PETALUMA, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Spectrum Antimicrobials, Inc., a subsidiary of Collidion, Inc. announces the development of a novel antiviral drug candidate designed to treat pulmonary infections.

Key Points: 
  • PETALUMA, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Spectrum Antimicrobials, Inc., a subsidiary of Collidion, Inc. announces the development of a novel antiviral drug candidate designed to treat pulmonary infections.
  • SPC-069 is a new class of therapy designed to treat viral, bacterial, and fungal infections in the lung and respiratory tract.
  • The Company plans to advance this drug candidate into human clinical studies as soon as possible with a partner or upon completion of its financing.
  • SPC-069 may become the first non-antibiotic, non-vaccine class of drug for the potential treatment of such pulmonary infections.

Collidion Announces Settlement of Sonoma Litigation

Retrieved on: 
Monday, November 12, 2018
Geography of California, California, Law, Sonoma, Misappropriation, Petaluma, California, Fiduciary

PETALUMA, Calif., Nov. 12, 2018 /PRNewswire/ -- Sonoma Pharmaceuticals, Inc. ("Sonoma") and Collidion Inc. ("Collidion") have today announced agreement to settle Sonoma's claims of trade secret misappropriation and breaches of fiduciary duty against Collidion and certain of Collidion's employees.

Key Points: 
  • PETALUMA, Calif., Nov. 12, 2018 /PRNewswire/ -- Sonoma Pharmaceuticals, Inc. ("Sonoma") and Collidion Inc. ("Collidion") have today announced agreement to settle Sonoma's claims of trade secret misappropriation and breaches of fiduciary duty against Collidion and certain of Collidion's employees.
  • In 2017, Sonoma filed a lawsuit against Collidion, Hojabr Alimi, Sameer Harish, and Monica Shaffer in federal district court, alleging the misappropriation of its trade secrets and confidential and proprietary information relating to hypochlorous acid products.
  • As part of the settlement, Sonoma will dismiss this legal action without any admission of wrongdoing by any Defendant.
  • The agreement is to the satisfaction of all parties, but the terms of the settlement are otherwise being kept confidential.